Microbot Medical Stock Analysis

Microbot Stock Analysis Notes

About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.76. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Microbot Medical recorded a loss per share of 0.45. The entity last dividend was issued on the 5th of September 2018. The firm had 1:15 split on the 5th of September 2018. Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To find out more about Microbot Medical contact Harel Gadot at 781 875 3605 or learn more at https://microbotmedical.com.

Microbot Medical Investment Alerts

Microbot Largest EPS Surprises

View All Earnings Estimates

Microbot Medical Thematic Classifications

Microbot Stock Institutional Investors

Note, although Microbot Medical's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Microbot Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 137.67 M.

Microbot Profitablity

Management Efficiency

Microbot Medical has return on total asset (ROA) of (0.2017) % which means that it has lost $0.2017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3187) %, meaning that it created substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.07 in 2026. Return On Capital Employed is likely to gain to -3.56 in 2026. Total Current Liabilities is likely to gain to about 4.7 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 5.2 M in 2026.

Technical Drivers

As of the 11th of February 2026, Microbot Medical secures the Mean Deviation of 3.52, downside deviation of 3.95, and Risk Adjusted Performance of 0.0237. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Microbot Medical, as well as the relationship between them.

Microbot Medical Price Movement Analysis

Microbot Medical Insider Trading Activities

Microbot Medical Outstanding Bonds

Microbot Medical Predictive Daily Indicators

Microbot Medical Forecast Models

Microbot Medical's time-series forecasting models are one of many Microbot Medical's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Microbot Medical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Microbot Medical Bond Ratings

Microbot Medical financial ratings play a critical role in determining how much Microbot Medical have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Microbot Medical's borrowing costs.

Microbot Medical Debt to Cash Allocation

Microbot Medical currently holds 111 K in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Microbot Medical has a current ratio of 5.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Microbot Medical's use of debt, we should always consider it together with its cash and equity.

Microbot Medical Total Assets Over Time

Microbot Medical Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Microbot Medical uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Microbot Medical Debt Ratio

2.01

It appears most of the Microbot Medical's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Microbot Medical's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Microbot Medical, which in turn will lower the firm's financial flexibility.

Microbot Medical Corporate Bonds Issued

Microbot Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Microbot Medical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Microbot shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Microbot Medical. By using and applying Microbot Stock analysis, traders can create a robust methodology for identifying Microbot entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Microbot analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Microbot analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Microbot Medical stock analysis indicators help investors evaluate how Microbot Medical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Microbot Medical shares will generate the highest return on investment. By understating and applying Microbot Medical stock analysis, traders can identify Microbot Medical position entry and exit signals to maximize returns.

When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.